Allergic conjunctivitis.

EENT Antiallergic Agents

1. Absorption: Low systemic absorption 2. Half-life elimination: ~3 hours 3. Excretion: Urine (60% to 70%, mostly as unchanged drug)

Hypersensitivity to olopatadine hydrochloride or any component of the formulation.

Olopatadine has minimal systemic absorption following ophthalmic administration. Systemic absorption would be required in order for olopatadine to cross the placenta and reach the fetus.

It is not known if olopatadine (ophthalmic) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering olopatadine (ophthalmic) to nursing women.

Cold symptoms (?10%), Pharyngitis (?10%), abnormal sensation in eyes (2% to 5%), blurred vision (2% to 5%), dry eye syndrome (2% to 5%), superficial punctate keratitis (2% to 5%), dysgeusia (2% to 5%)

Instill 1 drop into each affected eye twice daily (allowing 6 to 8 hours between doses).

Children ?2 years and Adolescents: Instill 1 drop into affected eye(s) twice daily, allowing 6 to 8 hours between doses.

There are no dosage adjustments provided in the manufacturer’s labeling.

There are no dosage adjustments provided in the manufacturer’s labeling.

Store at 4°C-25°C